-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2143 A Multicenter Real-Life Study of Polatuzumab Vedotin Combined with Immunochemotherapy in Patients with R/R DLBCL: Preliminary Data on Efficacy and Safety in Chinese Cohort

Program: Oral and Poster Abstracts
Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Poster II
Hematology Disease Topics & Pathways:
Non-Biological, Lymphoma (any), Diseases, Therapies, chemotherapy, Non-Hodgkin Lymphoma, DLBCL, Lymphoid Malignancies
Sunday, December 6, 2020, 7:00 AM-3:30 PM

Jianqiu Wu1*, Yanyan Liu2*, Li Fei3, Zhi-Jun Wuxiao4*, Fancong Kong3*, Zhihua Yao2*, Weilun Zhou4* and Jifeng Feng1*

1Jiangsu Province Cancer Hospital, Nanjing, China
2Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
3the First Affiliated Hospital of Nanchang University, Nanchang, China
4The First Affiliated Hospital, Hainan Medical College, Haikou, China


For patients with relapse/refractory(R/R) Diffuse Large B Cell Lymphoma (DLBCL), intensive therapy (such as R-ICE, R-DHAP) followed by autologous stem cell transplant (ASCT) can provide potential cure. However, not all patients would be eligible for such aggressive therapy. The ASCT ineligible or patients have very low survival rates and no curative options. Polatuzumab vedotin (Pola) is a conjugated antibody that delivers the microtubule inhibitor MMAE to CD79b-expressing cells. Pola administered in combination with Bendamustine-Rituximab (P-BR) has been approved for R/R DLBCL patients in USA and Europe consecutively. But real-life data of Pola on efficacy and safety in this setting especially in Chinese patients remain very limited.


This study aims to investigate the efficacy and tolerability of Pola with BR or R in R/R patients with DLBCL treated through a Compassionate Use Program (CUP) after failing ≥2 prior regimens.


We collected and analyzed the data of all patients enrolled in Pola CUP in four Chinese centers. Patients with R/R DLBCL who have exhausted all therapeutic options after at least 2 prior treatments could be enrolled in this program. Pola was administered at a dose of 1.8 mg/kg/cycle iv in combination with rituximab±bendamustine for a total of up to 6 cycles. Response was assessed after every 2 cycles and at end of treatment.


From Dec 12 2019 to Jul 30 2020, 27 patients were treated in the CUP of Pola and there are 20 patients whose diseases had already been assessed at least once for the response evaluation. Baseline characteristics of the 20 patients are shown in Table1. Nine patients received Pola-BR combination and 3 of them received the bendamustine combined regimen after the 3rd or 4th cycle in order to improve the efficacy. For the other 11 patients only Pola-R was administered. All patients received rituximab in front lines and 80.0%(16/20) of them are refractory to the prior therapy (no response or relapsed≤6 mon). 70.0% (14/20) patients had a high-intermediate or high risk disease (IPI score≥3); 10.0% (2/20) had ECOG performance status (PS) 3-4. 25.0% (5/20) patients had already received prior Car-T and 5.0% (1/20) had prior ASCT therapy.

At time of analysis, six patients finished all 6 cycles of treatment and 3 discontinued therapy due to personal reason or disease progression. The remaining patients are still in the process of treatment. The achieved overall response was Complete Response (CR) in 1 patients (5.0%) and Partial Response (PR) in 15 patients (75.0%). One patient progressed after 2 cycles of Pola-R therapy, but achieved PR after receiving Bendamustine combined therapy from the 3rd cycle. The overall response rate and treatment duration is shown in table 2 and Figure 1. The median follow-up is 48 days and the progression free survival (PFS) of the two progressed patients is 29 and 148 days. (Table 3 & Figure 2).

The main toxicity was hematological. Four patients developed grade 3-4 neutropenia (20.0%) and 2 patient (10.0%) had grade 3-4 thrombocytopenia. Febrile neutropenia was reported in 2 patients. One patient had pneumonia but recovered after anti-infection therapy. The adverse event of peripheral neuropathy was not observed.


For this R/R DLBCL cohort with heavily treated, high risk and refractory diseases, the Pola-(B)R regimen still achieved promising efficacy. However considering the limited sample size and short follow-up, more mature data and long-term survival outcomes is warrant.

Key words

Relapse/refractory; DLBCL; Polatuzumab Vedotin; Compassionate Use

Disclosures: No relevant conflicts of interest to declare.

<< Previous Abstract | Next Abstract
*signifies non-member of ASH